IL158038A0 - Allosteric adenosine receptor modulators - Google Patents

Allosteric adenosine receptor modulators

Info

Publication number
IL158038A0
IL158038A0 IL15803802A IL15803802A IL158038A0 IL 158038 A0 IL158038 A0 IL 158038A0 IL 15803802 A IL15803802 A IL 15803802A IL 15803802 A IL15803802 A IL 15803802A IL 158038 A0 IL158038 A0 IL 158038A0
Authority
IL
Israel
Prior art keywords
receptor modulators
adenosine receptor
allosteric adenosine
allosteric
modulators
Prior art date
Application number
IL15803802A
Other languages
English (en)
Original Assignee
King Pharmaceuticals Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King Pharmaceuticals Res & Dev filed Critical King Pharmaceuticals Res & Dev
Publication of IL158038A0 publication Critical patent/IL158038A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL15803802A 2001-03-19 2002-03-19 Allosteric adenosine receptor modulators IL158038A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/811,679 US6727258B2 (en) 1997-10-29 2001-03-19 Allosteric adenosine receptor modulators
PCT/US2002/008821 WO2002074056A2 (fr) 2001-03-19 2002-03-19 Modulateurs allosteriques des recepteurs de l'adenosine

Publications (1)

Publication Number Publication Date
IL158038A0 true IL158038A0 (en) 2004-03-28

Family

ID=25207237

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15803802A IL158038A0 (en) 2001-03-19 2002-03-19 Allosteric adenosine receptor modulators

Country Status (8)

Country Link
US (5) US6727258B2 (fr)
EP (1) EP1401441A4 (fr)
JP (1) JP2004536789A (fr)
CA (1) CA2441563A1 (fr)
IL (1) IL158038A0 (fr)
MX (1) MXPA03008524A (fr)
WO (1) WO2002074056A2 (fr)
ZA (1) ZA200210293B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7262017B2 (en) 2001-09-14 2007-08-28 Torrey Pines Institute For Molecular Studies Diagnostic markers for ischemia
US7202089B2 (en) * 2001-09-14 2007-04-10 Alan Kleinfeld Early diagnosis of stroke
US6825221B2 (en) 2001-10-18 2004-11-30 Allergan, Inc. Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain
ES2574918T3 (es) * 2003-06-02 2016-06-23 Isis Innovation Limited Tratamiento de la fatiga muscular
EP1648952B1 (fr) 2003-06-03 2018-03-07 THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Supplements alimentaires et compositions therapeutiques comportant des derives (r)-3-hydroxybutyrates
US20050085531A1 (en) * 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
EP1710233A4 (fr) * 2004-01-28 2009-07-15 Kissei Pharmaceutical Nouveau derive de benzofurane, composition medicinale contenant celui-ci et utilisations de celles-ci
EP2385375A3 (fr) * 2004-03-22 2012-02-22 FFA Sciences, LLP Développement et utilisation de sondes fluorescentes d'analytes non liés
US7978708B2 (en) * 2004-12-29 2011-07-12 Cisco Technology, Inc. Automatic route tagging of BGP next-hop routes in IGP
WO2006115134A1 (fr) * 2005-04-22 2006-11-02 Kissei Pharmaceutical Co., Ltd. Nouveau derive du benzofuranne, composition pharmaceutique le comprenant, et utilisation du derive ou de la composition
US20060257938A1 (en) * 2005-05-10 2006-11-16 Kleinfeld Alan M Method of screening for drugs that block ligand binding to a lipid binding protein
US20080108622A1 (en) * 2006-10-19 2008-05-08 Eisenach James C Combination therapy for the treatment of pain
US20080108603A1 (en) * 2006-10-19 2008-05-08 Eisenach James C Combination therapy for the treatment of pain
WO2008060841A2 (fr) 2006-10-27 2008-05-22 Ffa Sciences, Llc Utilisation de sondes pour métabolites non liés
US7897596B2 (en) * 2006-11-13 2011-03-01 King Pharmaceuticals Research & Development, Inc. Allosteric modulators of the A1 adenosine receptor
US7855209B2 (en) * 2006-11-13 2010-12-21 King Pharmaceuticals Research And Development, Inc. Allosteric modulators of the A1 adenosine receptor
US20090041839A1 (en) * 2007-05-23 2009-02-12 Beasley Martin W Pharmaceutical compositions for the treatment of pain
GB0722340D0 (en) * 2007-11-14 2007-12-27 Univ Leiden Sphingosine-1-phosphate (S1P) receptor compounds
DK2240017T3 (da) 2008-01-04 2019-06-17 Univ Oxford Innovation Ltd Ketonlegemer og ketonlegemsestere som blodlipid-sænkende midler
US20090281145A1 (en) * 2008-05-08 2009-11-12 Pier Giovanni Baraldi Allosteric enhancers of the a1 adenosine receptor
US8642654B2 (en) 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
GB201002983D0 (en) 2010-02-22 2010-04-07 Tdeltas Ltd Nutritinal composition
EP2914251B1 (fr) 2012-11-05 2019-08-21 The United States of America, as represented by The Secretary, Department of Health and Human Services Corps cétoniques destinés à protéger les tissus des lésions par rayonnement ionisant
GB201304467D0 (en) 2013-03-12 2013-04-24 Tdeltas Ltd Compound for use in protecting skin
SG11201507685UA (en) 2013-03-14 2015-10-29 Isis Innovation Process for producing (r)-3-hydroxybutyl (r)-3-hydroxybutyrate

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH540247A (de) * 1967-04-21 1973-09-28 Ciba Geigy Ag Verfahren zur Herstellung von heterocyclischen, Asthylendoppelbindungen enthaltenden Verbindungen
DE1908496A1 (de) * 1968-02-29 1969-09-18 Ciba Geigy Neue Thiophenderivate und Verfahren zu ihrer Herstellung
DE2204735A1 (fr) * 1971-02-05 1972-08-17 Yoshitomi Pharmaceutical Industries Ltd., Higashi, Osaka (Japan)
ES393101A1 (es) 1971-07-09 1974-05-16 Made Labor Sa Procedimiento para la preparacion de derivados de tieno- diazepina.
FI54312C (fi) 1972-05-09 1978-11-10 Sumitomo Chemical Co Foerfarande foer framstaellning av tieno-(2,3-d)pyrimidinderivat med avsoendring av urinsyra i urin utoekande
US4256755A (en) * 1980-04-28 1981-03-17 E. I. Du Pont De Nemours & Company Method of using N-substituted dihydro-2-oxazolamines as analgesics
DE3724031A1 (de) 1986-07-22 1988-01-28 Boehringer Ingelheim Kg Neue hetrazepine und verfahren zu ihrer herstellung
PH30676A (en) * 1986-07-22 1997-09-16 Boehringer Ingelhein Kg Hetrazepine compounds which have useful pharmaceutical utility
US5026698A (en) 1988-11-02 1991-06-25 Nissan Chemical Industries, Ltd. Thienopyridine type mevalonolactones
YU133090A (sh) 1989-07-12 1993-10-20 Boehringer Ingelheim Kg. Novi heteroazepini s paf-antaganostičnim učinkom in postopek za njihovo pripravo
JPH0511397A (ja) 1991-07-02 1993-01-22 Konica Corp レーザー光源用ハロゲン化銀写真感光材料
EP0638560A4 (fr) 1991-10-11 1995-03-29 Yoshitomi Pharmaceutical Medicament utilise pour traiter l'osteoporose et compose de diazepine.
JPH05345785A (ja) 1992-01-16 1993-12-27 Yoshitomi Pharmaceut Ind Ltd トリアゾロオキサゼピン化合物
TW263498B (fr) 1993-11-10 1995-11-21 Takeda Pharm Industry Co Ltd
JPH07304755A (ja) 1994-05-12 1995-11-21 Yamanouchi Pharmaceut Co Ltd 縮合ジアゼピン誘導体
WO1996014319A1 (fr) * 1994-11-08 1996-05-17 Takeda Chemical Industries, Ltd. Derives de thienopyridine ou de thienopyrimidine et leur utilisation
JPH08337583A (ja) 1995-04-13 1996-12-24 Takeda Chem Ind Ltd 複素環化合物およびその製造法
CN1216546A (zh) * 1996-04-25 1999-05-12 武田药品工业株式会社 噻吩并吡啶衍生物及其用途
DE19642451A1 (de) * 1996-10-15 1998-04-16 Merck Patent Gmbh Aminothiophencarbonsäureamide
US5939432A (en) * 1997-10-29 1999-08-17 Medco Research, Inc. Thiophenes useful for modulating the adenosine receptor
US6323214B1 (en) * 1997-10-29 2001-11-27 Medco Research, Inc Allosteric adenosine receptor modulators
WO1999046267A1 (fr) * 1998-03-12 1999-09-16 Novo Nordisk A/S Modulateurs de proteine tyrosine phosphatases (ptpases)
US6713638B2 (en) * 2001-05-18 2004-03-30 Joel M. Linden 2-amino-3-aroyl-4,5 alkylthiophenes: agonist allosteric enhancers at human A1 adenosine receptors

Also Published As

Publication number Publication date
US7112607B2 (en) 2006-09-26
US20020143004A1 (en) 2002-10-03
US20010047008A1 (en) 2001-11-29
EP1401441A2 (fr) 2004-03-31
ZA200210293B (en) 2003-12-19
US20020147185A1 (en) 2002-10-10
WO2002074056A2 (fr) 2002-09-26
US20020147231A1 (en) 2002-10-10
JP2004536789A (ja) 2004-12-09
US6727258B2 (en) 2004-04-27
MXPA03008524A (es) 2004-06-30
EP1401441A4 (fr) 2006-09-06
CA2441563A1 (fr) 2002-09-26
WO2002074056A3 (fr) 2003-10-09
US20040077630A1 (en) 2004-04-22

Similar Documents

Publication Publication Date Title
IL158038A0 (en) Allosteric adenosine receptor modulators
IL150912A0 (en) Adenosine receptor modulators
IL159594A0 (en) Adenosine a3 receptor modulators
HUP0401437A3 (en) Adenosine a3 receptor agonists
GB2384570B (en) Modulators
PL374215A1 (en) Selective estrogen receptor modulators
GB0128953D0 (en) Fixing device
AU2003237492A1 (en) Urotensin ii receptor modulators
DE69835024D1 (de) Allosterische adenosin-rezeptor-modulatore
GB0123379D0 (en) Modulators
GB2376290B (en) Filling means
IL154654A0 (en) Osteoclast-associated receptor
EP1581309A4 (fr) Modulateurs de kinase
GB0000474D0 (en) Receptor
AU1252102A (en) Receptor
GB0102876D0 (en) Triboluminescent devices
PL370980A1 (en) Benzothiophenes as adenosine receptor modulators
EP1374911A4 (fr) Agents permettant de mesurer la capacite de la pyrimidine a etre metabolisee
IL158642A0 (en) Naphthothiazine positive allosteric ampa receptor modulators (paarm)
HK1064292A (en) Allosteric adenosine receptor modulators
GB0112649D0 (en) Macrophage receptor
GB0215389D0 (en) Receptor
EP1404353A4 (fr) Procedes d'utilisation d'un recepteur du hyaluronane
HK1074442A (en) Adenosine a3 receptor modulators
GB0121905D0 (en) Fixing devices